Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine
(MENAFN- atccoms) Plainsboro, New Jersey, US and Bagsværd, Denmark, November 18, 2026 – Today, Novo Nordisk shared primary results from the phase 3 STEP Young trial evaluating the safety and efficacy of investigational once-weekly semaglutide injection, with a maximum dose of 1.7 mg or 2.4 mg based on baseline body weight, in combination with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years with obesity.1 The results were presented during a scientific symposium at ObesityWeek® 2026 and simultaneously published in The New England Journal of Medicine.1,3
“Severe obesity can profoundly affect a child’s physical health, emotional well-being, and daily life. This chronic disease also increases the risk of many obesity-related complications that can emerge early and persist into adulthood,” said Ania M. Jastreboff, MD, PhD, Professor of Medicine (Endocrinology) and Pediatrics (Pediatric Endocrinology) at Yale School of Medicine and Director of the Yale Obesity Research Center (Y-Weight). “Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child’s trajectory back towards one of improving weight related health.”
In the STEP Young trial, more than 85% of the children had class II or III severe obesity at baseline, corresponding to BMI thresholds of ≥35 kg/m² and ≥40 kg/m², respectively. At week 68, for the efficacy estimand, the estimated mean percentage change in BMI from baseline was -17.4% with semaglutide and +2.2% with placebo, for an estimated treatment difference of -19.7 (95% CI: -23.1 to -16.2)*.1 For the treatment regimen estimand, the estimated mean percentage change in BMI from baseline was -13.5% with semaglutide and +2.7% with placebo, for an estimated treatment difference of -16.2 percentage points (95% CI: -19.4 to -12.9; p60 kg, or 1.7 mg if baseline weight was 45-60 kg, or maximum tolerated dose.1
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel, and sustain now and in the future. Every day, over 66,500 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programs, and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. In the United States, Novo has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment